Simon Garfield on Zaha Hadid’s new Maggie’s Centre 
Guardian Unlimited - Oct 30 4:17 PM
Simon Garfield on the centres aiming to help cancer patients ‘feel hugged by a building’.Save to My Web

Acupuncture, Turmeric May Help Ease Arthritis 
HealthDay via Yahoo! News - Oct 30 9:04 AM
MONDAY, Oct. 30 (HealthDay News) — Acupuncture and an extract of turmeric — the spice that gives curry its kick — may both offer significant pain relief to some arthritis patients, two new studies suggest.Save to My Web

BIOLASE Conference Call: 2006 Third Quarter, Nine-Month Results 
RedNova - 46 minutes ago
IRVINE, Calif., Oct. 31 /PRNewswire-FirstCall/ — BIOLASE Technology, Inc.Save to My Web

Three New Lung Tumor Subtypes Identified In DNA Profiling Study 
Science Daily - Oct 31 3:17 AM
A new study has identified three subtypes of non-small-cell lung cancer tumors, a finding that may provide valuable clinical information about patient survival in early- or late-stage disease, how likely the cancer is to spread and whether the tumor will prove resistant to chemotherapy.Save to My Web

Biofeedback Pain Relief Device First of its Kind to be Registered with FDA 
[Press Release] PR Web via Yahoo! News - Oct 30 4:00 AM
New Windsor, NY (PRWEB) October 30, 2006 — After passing its preliminary registration phase with the FDA, Ondamed is now awaiting final approval to be officially listed with the government agency as an effective pain-treatment device.Save to My Web

Searching for an end to sickle cell pain 
The State - Oct 25 9:08 PM
Teething pains landed Kharlybia Roane in the hospital when she was just months old. Youngsters who have sickle cell disease can find even growing pains agonizing. But many don’t get good pain relief with standard treatments, and asking for more pain medicine can get them labeled as “drug-seeking.”Save to My Web

Study Shows Treatment With BARACLUDE(R) (Entecavir) Resulted In Greater Viral Load 
Medical News Today - Oct 31 12:12 AM
Bristol-Myers Squibb Company (NYSE: BMY) today announced results of an open-label, randomized study of 65 antiviral naive chronic hepatitis B e-antigen (HBeAg) positive patients, showing that patients receiving the oral antiviral therapy BARACLUDE(R) (entecavir) demonstrated greater viral load reduction at weeks 12 (primary endpoint) and 24 than patients treated with adefovir. [click link for Save to My Web